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 SOURCES
Dioxin gets into the food chain by bioaccumulating in organisms in the food chain. How
does it get into the food chain environment? Some dioxins are directly eliminated into
water, for example, from pulp and paper mills. Most dioxin is released directly to the
atmosphere and is subsequently distributed worldwide through atmospheric transport.
Dioxin is very sticky, it binds to particles, is picked up on dust particles in the winds and
is blown around. Nowhere in the world today is free from dioxin. This is a worldwide
contaminant and can be found, with sensitive analytical techniques, even in the most
remote places on earth.
When was dioxin first found in the environment, and when did it start to accumulate?
Some chemical companies have been trying to convince us for a long time that dioxin has
been around since the beginning of time, and that it is a product of forest fires and vol-
canic activity. Prior to the onset of heavy uses of chlorinated organics in industry, which
really commenced about 1930, levels were extremely low, based on analysis of sediment
samples. People have done analyses of Egyptian mummies from more than 2,000 years ago
and frozen Eskimos from northern Canada and the levels are below the detection limit.
Dioxin is a product of the modern industrialization.
Other than forest fires and volcanos, what are the other major sources? I think it is a point
to remember that, unlike polychlorinated biphenyls (PCBS), dioxins and dibenzofurans
have no known industrial use and they were never made for any purpose. They are
contaminants of industrial processes involving certain organic compounds and chlorine.
They are produced by lowtemperature combustion at between 300° to 400° degrees centi—
grade. To destroy dioxins, you have to go to over 12000 centigrade. But you can form them
at combustion temperatures characteristic of wood burning in wood- burning stoves. In
addition, dioxin is a product formed by the chlorine bleaching of paper and pulp prod-
ucts. The paper industry has been very responsible in decreasing their use of chlorine
bleach, and thereby tremendously decreasing their input of dioxin and dibenzofurans into
the environment. Of course, that is after 50 years of heavily contaminating the sediments,
which give us a long-lasting problem.
What are the other sources of dioxins? In the US. Environmental Protection Agency (US.
EPA) dioxin reassessment, there was an attempt to use total mass balance equations to
determine where the dioxin is coming into the environment. A number of environmental
monitoring studies indicate that the levels do not appear to have declined since the mid to
late 19805. This suggests that we still have inputs as well as outputs, and that we are in a
pseudo steady state. In the Great Lakes, there was a peak of dioxins in the early ’703 and
since then levels came down until about 1987. In the U.S., the major new sources of
dioxin appears to be hospital incineration. In Germany it appears to be municipal waste
incineration. It is not a major source here because we use landfills but, if we switched to
municipal incineration, it may become a major source in the US. If anyone knows about
hospital waste incineration, they are totally unregulated and they burn at very low tem-
peratures, they have tremendous amounts of chlorinated plastics, and therefore lots of
dioxin are potentially emitted from them. Diesel exhaust also appears to be a source of
dioxin. Metal smelting and refining appears to be another source, but we really don’t have
a good mass balance. In summary, we can account for about 50% of the new input into
the environment, and we are uncertain where the rest is coming from.
EFFECTS
A typical toxic substance goes into the body and kills cells, or does one particular thing.
In contrast, dioxin does a lot of things and should be considered as a hormone. I don’t
know what it is a hormone for, in terms of the natural sense. Hormones go into the body
and they have different effects on different tissues, they can have different effects at
2
 different stages of development of the tissue, and they can have different effects on differ—
ent species. I think we can say the same thing about dioxin. So you see a great deal of
tissue specificity, developmental stage specificity, or age specificity, or species specificity
1n response.
At very high doses, in all species we have looked at, dioxin causes death. But, again, it is
not your typical pesticide kind of death, where you know you give a lot to the animal and
it goes four legs up in the air immediately. Death is usually preceded by a wasting syn-
drome, the animals can easily lose 50% of their body weight before they die and, depend-
ing on the animal, the time to death varies. So it takes guinea pigs about two weeks, mice
take about three weeks, so do rats approximately, monkeys take about six weeks to die, for
example. It is an inexorable process. If the level of dioxin administered to the animal,
either acutely or following repeated exposure, once they reach a certain body burden, it is
like a switch is thrown and the animal will, approximately x number of weeks later, die.
We really don’t know what they die of. You can, for example, feed the animal and prevent
the wasting, and they still die. 80 it is not just because they used up their body glycogen.
The highest levels that we know that people were exposed to, would have been lethal in
guinea pigs, but they are, at least in the order of magnitude or more, lower than the levels
that would kill almost any other mammalian species. 80 I think that the reason we have
not seen wasting or death in people is we may not have had high enough exposure, and
that is not an experiment I think we are going to try.
At levels below that where you see wasting, you can see effects on the lymphoid tissues
and you actually have loss of the thymus and spleen and at slightly lower levels, and in
the adult male you can have atrophy of the testis. But, again, these are all relatively high
dose effects. Effects on the liver -- there are some differences in different species but, in
general, you see enlargement of the liver, you see accumulation of fat in the liver. In some
tissues, you have hyperplasia, which is a proliferation of cells. The tissue actually gets
bigger from having more cells, and this occurs in the lining of the gastro—intestinal tract, it
occurs in the lining of the urinary tract, and it occurs in the bile duct, which comes from
the liver.
In other kinds of cells, instead of getting hyperplasia, which is an inappropriate prolifera-
tion of cells, you get squamous metaplasia, which is an inappropriate differentiation of
cells. It is not that an eye turns into an ear, but in fact one type of cell turns into another
type of cell. It starts behaving differently. So, one of the classic kinds of symptomatology
that we see, not only in monkeys for example, butalso in humans, is metaplasia of the
meibomian glands of the eye. Now, meibomian glands are little glands at the base of your
eyelid that secrete very small amounts of ﬂuid. With exposure to dioxins, these actually
change and start producing waxy exudates on your eye that makes vision very difficult and
this is a complaint of people who have had very high levels of dioxin exposure. They also
complain'of problems with hearing. There are glands that line your ear canal which are call



















be possible to monitor exposed people by collecting some of their earwax and measuring
the concentrations of dioxin and related chemicals in the earwax. It will be a little hard to
do mass balance equation to calculate their whole body burden, but it might be an accessi—
ble source of tissue where you could find out whether there had been exposure.
Chloracne has been the hallmark of dioxin toxicity. This is not the ordinary teenage acne,
but a very, severe persistent form of cystic acne. People who had been exposed over 40
years ago to dioxins in industrial accidents are still having active Chloracne, not limited
just to their face and back, but all over their bodies. It is characterized by hyperplasia,
which is a proliferation of cells, by hyperkeratosis, which is an altered differentiation of
the cells, and by changed pigmentation. It is a very severe condition. You could say it is




Dioxin is a potent teratogen in a number of species in that it causes actual gross structural
abnormalities, cleft pallet, and hydronephrosis in mice. In other species, it causes much
more subtle developmental effects. Effects that, until the last couple of years, we were not
really aware of, because they are the kind of effects that you do not see in a standard
teratology study. In a standard teratology study, you dose animals during organogenesis,
which is the major period of differentiation of the different organs and tissues, and then
you sacrifice them just before they would normally be born. The developmental effects we
are studying now in fact are things that you do not see until the animal reaches puberty,
and then there are alterations in the sexual functions and reproductive behavior of the
animals. So, if you kill the animals at birth, you are not going to see what is going to
happen.
 
I will talk a little bit more about cancer. Dioxin appears to be a carcinogen in fish, rodents
and other mammals, including humans. But dioxin can also modulate the immune system
resulting in an inability to fight disease. It is a very powerful immunosuppressant. It can
also upregulate the immune system so that you start becoming hypersensitive, start devel-
oping autoimmunity and allergies. Depending upon the stage of the animal and the
species, sometimes you observe immunosuppression and in other cases you observe
upregulation.
BIOCHEMICAL EFFECTS
Dioxin causes a wide variety of changes in enzyme levels and causes biochemical effects
(Table 1). There has been some discussion about whether these changes represent adverse
effects or just biological responses. I think many of them can be considered as biomarkers
of the potential for other effects to happen. These changes in enzyme levels, including
increases and decreases in the synthesis, leads to alteration in metabolism of both endog-
enous and foreign compounds. For example, it affects the way we handle glucose metabo-
lism, induces cytochrome P4501A1 and P4501A2 and regulation of other kinds of
enzymatic activity.
   
TABLE 1: BIOCHEMICAL EFFECTS OF TCDD:
TABLE 2: BIOCHEMICAL EFFECTS OF TCDD:
ENZYME INDUCTION


















Results in Altered Homeostasis
Results in Altered Metabolism
 
 Dioxin modulates many hormone
Systems and their receptors (Table 2). TABLE 3: BIOCHEMICAL EFFECTS OF TCDD:






























rhythm. It affects estrogen, androgens,
glucocorticoids and insulin. Dioxin
causes the modulation of growth
















hormone systems, you alter the
homeostasis of the animal and switch
how the animal behaves. For example, Tumor Necrosis Factor on
dioxin can act both as an anti-estrogen
by blocking estrogen activity in the
Epidermal Growth Factor
Transforming Growth Factor (1











































circulating thyroid hormones in, for
example, rats, but it causes increasing
levels of circulating thyroid hormones






























































yourself at risk for problems.
 
















































































































































































































































































































































































































































































































































































TCDD heat shock proteins


























Figure 1. Model of Mechanism of Action of TCDD and Ah Receptor.
Two Roles of AhR?







Transcriptional Enhancer Tyrosine Kinase
 
Figure 2. Two Roles of AhR?
  
they are developmentally regulated. You have the possibility that, at different stages, these
may function differently in controlling the ability of the receptor to bind the ligand.
There is the possibility that amt, the second protein which is actually involved with the
DNA binding, is part of a family of proteins. TCDD bound to a receptor can interact with
amt 1, amt 2, amt 3, amt N to form this heterodimer, the two protein complex. Each of
these will only recognize one specific gene. So we have multiple levels of interaction
going on here. We have multiple transcription factors, multiple DNA recognition sites,
and we also know that even the Ah receptor, which at one point in time we thought was
the product of a single gene, has multiple alleles of that gene so that there are Ah receptors
that are slightly different sizes. We do not know yet about the specificity of the receptors
and whether the receptor for the protein with a size of 106 kilodaltons will accepted the 97






































































































































































































































































































































































































































































































































































































































































































































































































































































this network, and sending out signals in all directions.
COMPARATIVE TOXICITY
There is a wide variation in acute toxicity of TCDD to adult mammals (Table 4). The
guinea pig dies a week or so after being exposed to dioxin, whereas hamsters survive until
you get to very high doses. You have approximately 3-5,000 fold differences in sensitivity.
For many chemicals this is highly unusual. For something that functions like a hormone,
this is not totally unexpected. But the point that I want to gather is that, while guinea pigs
are exquisitely sensitive, and I am going to stress that these are adult guinea pigs, and
adult hamsters are very resistant, most mammals tend to cluster in the neighborhood of
100 micrograms per kilogram as approximately the lethal dose. 80 while the guinea pigs
and the hamsters are outlyers for this response, most animals are similar. I stress the point
about adult hamsters versus adult guinea pigs because if you look at hamster embryos or
fetuses, they are essentially equisensitive to guinea pig embryos. If you look at rat em—
bryos, they are essential equisensitive. There is something about the adult hamster that
makes them resistant to TCDD, but the embryo responds at the same concentration as lots
of other species.
With respect to dioxin, people react
TABLE 41 ACUTE TOXICITY 0F TCDD similarly to animal responses. Biology is
   
inherently conservative and things tend to
SPECIES LD (pg/kg) work the same way in many species.
Guinea pig 0'6 _ 2.5 There is a large amount of data showing,
for example, that changes in biochemical
Mink 4 properties such as enzyme induction, in
Rat 22 _ 320 some hormonal states and in growth
factors occur at similar body burdens in
Monkey <70 animals as they do in people. For exam-
, ple, in the ongoing occupational study
Rabblt 115'275 conducted by National Institute of Occu-
Mouse 114-280 pational Safety and Health (NIOSH)
looking at workers who were exposed to
Dog >100 ' <3,000 dioxin, these adult males are showing
Hamster 1 150 _ 5 000 decreases in the levels of their circulating
’ ’ testosterone at body burdens very similar
to the body burdens in adult rats. In
immunotoxicity testing, human
lymphocytes and cultured cells respond to the same concentration of dioxin in the media
as mouse and monkey cells. In terms of developmental toxicity based on organ culture
you find similar responses at similar concentrations of TCDD. For example, if you take out
the embryonic palate of a rat and the embryonic palate of a human, put them in culture
and expose them to the same concentration in the media, you get a similar response.
Similarly, the body burden associated with chloracne in people is essentially the same as
the body burden causing chloracne in monkeys, in hairless mice, or in rabbit ears. Ani—
mals with a lot of hair -- like regular mice and regular rats -- do not develop chloracne, but
hairless mice do and the body burden there is essentially the same. Cancer appears to
occur at similar body burdens in animals as in humans.
SUBTLE DEVELOPMENTAL EFFECTS
I will just mention some really recent data on subtle developmental effects that you would
not see if you only looked when the animals were born. Dick Peterson at the University of
Wisconsin is doing some very important mammalian work. A year ago he reported that if
he treated pregnant rat dams towards the end of gestation with a very low level of dioxin,
as low as 65 nanograms per kilogram, it resulted in demasculinization and feminization of
the male offspring. Most of these changes were not detectable until they reached puberty.
8
  
We have since repeated that study, not only with his kinds of rats, but also in another
strain of rats. We have also looked at hamsters, and we get basically the same result. We
see decreased sperm count, altered sexual behavior, and shortened genitalia in these male
rat pups. We have looked at both female rat and female hamster pups and we see even
more dramatic changes in the females, where we see hypospadias, which is where the
urethra, instead of emptying in a separate opening at the top of the clitoris, actually emp-
ties into the vagina. We see complete clefting of the clitoris, and a cleft being maintained
all the way down to the vagina. In the rats, we see delayed vaginal opening and, in some
cases, no vaginal opening. In the hamsters we cannot even find an external vagina in
some cases. Clearly, the animals with no vaginal opening are not going to be fertile.
Although these animals appear to be cycling perfectly normally and the ovarian-pituitary
axis appears to be functioning properly, we do not really understand the mechanism of
what is going on and we are trying to explore it.
These are very concerning events and Dr. Guo from Taiwan, who is one of the principle
investigators on the Yucheng cohort, visited my lab two days ago. This is the PCB rice oil
poisoning in Taiwan in 1979, where about 2,000 people unfortunately cooked with rice oil
that was contaminated with PCBs that were themselves contaminated with the
polychlorinated dibenzofurans. The children born following this episode have been
followed for the past 8—13 years, that is the age of the kids now. When they were first born
they were reported to have what was called ectodermal dysplasia syndrome, which in-
cluded all sorts of pigmentation problems, problems with their nails and dentition, and
they were small in stature. When they did development milestones, these kids were
developmentally delayed. They have continued to follow these kids. Their IQ is shifted




































































































































































































































hamsters. In addition, work from the ANIMAL STUDIES
US. EPA laboratory has indicated that
dioxin causes increases of tumors in
medaka, at multiple sites and short
latency and at high incidence.
OMammals - 18 studies
All positive
Rats, mice, hamsters















































numbers of studies that said, yes, dioxin
does cause tumors in people and, no, it
doesn’t. The advances that these three
High incidence
  
studies (Fingerhut et al. 1991, Manz et al.
TABLE 6’5 DIOXIN IS A CARCINOGEN‘ 1991, and Zober et al. 1990)* have are that
HUMAN EPIDEMIOLOGY they have blood levels for the cohorts. So
 
they can actually validatetheir exposure in
Three recent occu ational cohorts , , _ _ . ,
p then industrial hygiene matrlces w1th serum
Zober et al. ’90 levels of dioxin. In that case you find an
increased standardized mortality ratio
Fingerhut et al‘ ’91 related to exposure to dioxin, especially in
Manz et (IL ’91 the people who were exposed long term;
_ ’ people with at least 20 years of exposure.
'Incréased Standardlzed mortahty This was a generalized tumor response. I
ratlos related to exposure think you are all familiar with diethyl
.Generalized tumor response stilbestrol (DES) that specifically caused
  
vaginal adenocarcinoma in young women.
The specificity of the lesion is why we were
able to find out that this was a problem. If
you have something that causes a generalized increase in cancer, it is very hard to pick up.
There is a suggestion from two of these studies that there may be an increase in lung
tumors. Well, with the background as high as it is in lung tumors, it is very hard to pick
up a small number of extra cases. But in fact these studies are all very compatible with
each other, showing that high levels of exposure to dioxin are associated with an increase
in cancers overall.
There is another study that will be published in the September issue of the American
[ournal of Epidemiology, based on the Seveso cohort. Seveso was a town in Italy, and in
1976 there was an explosion at a trichlorophenol plant and the area around it was highly
contaminated. The serum levels in some of those people were the highest that we have
ever seen. Until now there has been a suggestion in a report published in 1989 that there
might be a increase in cancer, but it was just too soon, and the numbers were too small.
This paper in press now actually demonstrates, based on cancer registry data in that area
of Italy for 11 years since the explosion, there are very significant increases in multiple
types of tumors in that population. Now that you think it is all bad, there is also a de-
crease in breast cancer. Remember I told you dioxin is a hormone, and it may increase
some things and decrease other things. The decrease in breast cancer, by the way, has
been reported in animal studies. In this report on the Seveso study to be published, the
increase is in both males and females, and again at multiple sites. I really find it hard to
accept the negative, or the null hypothesis. To me, the data is overwhelming that dioxin
has the potential, at least at high doses, to result in cancer in people.
*Fingerhut, M.A., W.E. Halperin, D.A. Marlow, L.A. Piacitelli, P.A. Honchar, M.H.
Sweeney, A.L. Greife, P.A. Dill, K. Steenland, and AJ. Suruda. 1991. Cancer Mortality in
Workers Exposed to 2,3,7,8—tetrachlorodibenzo—p-dioxin. The New England journal of
Medicine. 324:212—218.
Zober, A., P. Messerer, and P. Huber. 1990. Thirty-four—year mortality follow-up of BASF
employees exposed to 2,3,7,8-TCDD after the 1953 accident. International Archives of
Occupational and Environmental Health. 62:139-157.
Manz, A., J. Berger, ].H. Dwyer, D. Flesch-Ianys, S. Nagel, and H. Waltsgott. 1991. Cancer








































































































































































































levels of exposure to diox1n before








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TABLE 8: RELATIVE POTENCY
(CLEFT PALATE)
   
ABirnbaum et al., 1987
BBir'nbaum et al., 1991
CMiller & Birnbaum, 1986
These chemicals all act by the same
mechanism, and we should be able to assign
them relative potency rankings. The toxic
TCDDA 1.000 equivalency scheme is a scheme of relative
B potency ranking. These compounds are
TBDD .235 considered as if they were a dilution of
TCDFA .049 TCDD. So you weight them and if you
TBDFB .100 assign TCDD a value of. 1, you can see that.
the brommated d10x1n IS about 1/4th as tox1c
1,2,3,7,8-PEBDF .026 as TCDD itself. The tetrachlorodibenzofuran
is only l/20th as toxic despite looking like
1’2’3’7’8'PECDFA '004 TCDD and binding very tightly to the
2,3,4,7,8—PECDF“ .095 receptor. It is much less persistent than
2 3 4 7 8 PEBDFB 005 TCDD and is readily metabolized in the
’ ’ ’ ’ ' ' mammalian systems, so the exposed animal
HCDF" .010 can get rid of it, since metabolism for these
HBNC 002 chemicals is a detoxification process. The
‘ brominated-dibenzofuran is more toxic than
2,3,4,5,3’,4’-HCBA ,00003 the chlorinated, while for the dioxin it is the
reverse, because the brominated—
dibenzofuran is harder to metabolize than
the chlorinated. You can rank these com-
pounds (Table 8) according to their relative
effect. This was done for cleft palate, and it
has been used in the development of toxic equivalency factors (TEFs) and many other
kinds of end points have also been used. For example, receptor binding I have already
mentioned. Induction of biochemical responses, like enzyme induction, and this can be
done either in the animal in Vivo or can be done in test tubes with cultured cells,
teratogenicity, effects on the skin, dermal toxicity, immunotoxicity, or tumor promotion.
All these things have been used, and looked at in total to come up with a toxic equiva—
lency scheme. The US. EPA came out with interim TEFs in 1989, which I think is essen-
tially identical to the NATO values also today being used by Scandinavian countries, and I
think Canada uses the same numbers for the dioxins and furans.
The question is, what about the dioxin—like PCBs? The US. EPA is determining values for
TEFs for the dioxin-like PCBs in fish, we have been looking at them in a long term mouse
study, and Health and Welfare Canada has been looking at them in a long—term rat study.
What we are finding is similar, which is that while the dioxin-like PCBs must be consid-
ered in any kind of assessment, in most cases they are not going to drive the re-assessment.
Congener No. 77 binds the receptor very well, but it is very rapidly metabolized in mam-
malian species and by many fish. So its in Vivo toxicity is much less than you would
predict based on something you did in culture. On the other hand, birds have very lim—
ited ability to metabolize these compounds, so you want to assess the toxicity for birds,
using in Vitro tests, while for species that can metabolize it, you may want to use in vivo.
In other words, TEFs have to be applied with a certain degree of thought behind them.
Birnbaum, L.S., M.W. Harris, D.D. Crawford, and RE. Morrissey, 1987. Teratogenic
Effects of Polychlorinated Dibenzofurans in Combination in C57BL/6N Mice. Toxicology
and Applied Pharmacology. 91:246-255.
Miller, CF. and LS. Birnbaum. 1986. Teratologic Evaluation of Hexabrominated
Naphthalenes in C57BL/6N Mice. Fundamental and Applied Toxicology. 7:398—405.
L.S. Birnbaum, R.E. Morrissey, and M.W. Harris. 1991. Teratogenic Effects of 2,3,7,8-
Tetrabromodibenzo-p-dioxin and Three Polybrominated Dibenzofurans in C57BL/6N Mice.







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































like PCBs would protect us against the non-dioxin-like PCBs. Our current “dioxin” expo-
sure is somewhere in the neighborhood of maybe 30-50 parts per trillion on a toxic equiva—
lency basis, derived primarily through the food. This kind of body burden of dioxins and
furans is associated with exposure to about 1-3 picograms per kilogram per day. But
nursing infants and subsistence fishermen may have higher levels of exposure.
So I think there are two views that can be looked at. The first one is, are current levels in
the environment a problem? The second is that if we do not think they are a problem,
should we worry about these special populations, the nursing infants and the subsistence
fishermen? Do the current levels have the entire population on the brink of some kind of
biological response? I am purposely vague, I am not saying adverse effect. Death is clearly
an adverse effect, but is alteration of your hormonal status an adverse effect? I am not
sure. It probably depends in what environment you find yourself. You know if your
glucocorticoid levels are already elevated and then you are stressed, you might have a lot
more problems than someone else. But are we at the level of beginning to expect re-
sponses? In fact, are there people in the population who are already experiencing subtle
health effects? I should mention that male sperm count has dropped over 50% in the last
50 years, the incidence of endometriosis in the human population has increased dramati-
cally, the age of menarche has decreased dramatically and this cannot all be accounted for
by nutritional changes. I mean there are definitely things going on there. There is a recent
suggestion that elevated levels of DDT are associated with increased incidences of breast
cancer. Are there subtle things going on? I don’t really know the answer to that but, if
they are, then clearly, any increase of individual exposure would be undesirable.
EPA DlOXlN REASSESSMENT
Now, before I tell you what I think, I just would like to brieﬂy mention the dioxin reassess-
ment. About three years ago, there was a meeting on dioxin at the Banbury Center in
Connecticut and, when we came back from it, I was really excited. I was also real naive. I
had just joined the agency, so I wrote Erich Bretthauer a memo telling him I thought this
was an opportunity for the agency to get in front of the issue, instead of always coming in
at the rear, and that there was enough new information that had been gathered about the
effects of dioxin that we really ought to reassess its risk. In fact, Bill Reilly, a little over
two years ago, decided that we would do that and we started a multi-faceted approach
including a bioaccumulation project and an aquatic toxicity project. There are many other
parts of this reassessment. There has been evaluation of the literature, which has been
ongoing. This is a critical review of the new literature. There have been eight chapters
written, and they have been done by outside experts in conjunction with US. EPA people
as well. These were peer reviewed last September at a meeting and have been undergoing
re—evaluation and updating really since that time. There is also analysis of the exposure
information. I should say there are actually eight to nine revised chapters that will be
available shortly, the exposure scenario was also reviewed last September and that has
been revised, and there are three volumes of exposure assessment. We have been looking
more closely at human tissue levels, in collaboration with colleagues at the Center for
Disease Control (CDC). We have been doing a lot of data collection, because what we
wanted to do was try to develop extrapolation models that would be biologically based.
There was some data that we felt we were missing, and we tried to identify the most
sensitive responses that we could measure and obtain better estimation of the toxic equiva—
lency factors for the coplanar PCBs. All these different kinds of bench and laboratory
science have been ongoing and are feeding into a risk characterization. We had originally
hoped this would be done by now, but we have been held up by the epidemiology because
all this new information which is just coming out, for example, the paper in press about
cancer in Seveso, needs to be incorporated into the document. I think we are currently
looking at public release of drafts of these documents probably in about October, which
means that they would be taken to our external Science Advisory Board for review in
probably January or February.
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David Villeneuve, Health and Welfare Canada: You have made reference to neurobehavioral
effects in connection with the Yucheng study, I believe, and PCB and dibenzofurans. Is
there any indication whatsoever that dioxins are perhaps implicated in neurobehavioral
effects?
Linda Birnbaum: Yes, there is. Prenatal exposure of monkeys appears to result inaltered
spatial memory. You can tell monkeys that they are supposed to remember where a certain
object is, and the dioxin—exposed monkeys have much more trouble with this short- term
spatial memory than animals who were not prenatally exposed. Most of the Yusho and
Yucheng data on responses is purely correlative, but if you try to associate them with the
level of PCBs or the level of dibenzofurans they correlate with the dibenzofurans level
much more than the PCB level for most of those things. So we know that certain PCBs,
like some of the non-dioxin-like PCBs, are developmentally neurotoxic, but dioxin itself
also appears to have a different spectrum of developmental neurotoxicity. Clearly, the














































































































































































































































































































































































































































































































































































































































































































 Linda Birnbaum: If you take the human data. Well, you can do it two ways. You can take the
Kociba data and predict the human response —- what would be elevated risks -— and it
comes out right in the ballpark of Fingerhut, Zober and Manz. You can take the Fingerhut
data and predict what the animal tumor incidence would be, and it comes right out. In
fact, the Fingerhut data would actually predict more tumors in animals than Kociba.
Tony Wagner, Environment Canada: Your last slide in your off-the-record comment, do some
people take that as the first step of organized brinkmanship?
Linda Birnbaum: I’m not sure I know what organized brinkmanship means.
Tony Wagner: We are at a critical stage —- either ban it or mount a massive cleanup.
Linda Birnbaum: The last slide was the conclusion of our outside peer panel. On the last day
of the peer review, they actually sat there and they listed effects, and they listed body
burdens that were associated with the effects in animals, and then they listed the body
burdens associated with effects in people. I should really stress, this is a TEQ. If all you
are worried about is dioxin, the levels of dioxin by itself, are probably not that high. But
when you look at the sum total of what is out there, that is where the body burdens may be
high enough so you might say we are having a response. Your question about ban it or not
banning it -— I mean, what are you going to ban? We don’t even know where half this stuff
is coming from. My feeling, and this is purely my opinion, I have actually heard industry
people say this and this is totally off the record, is that the total level of halogenated
aromatic organics in the environment is higher than they should be.
Denis Davis, Environment Canada: Do you have the historic body burden trends?
Linda Birnbaum: That is a really good question but we don’t have the information, Well, if you
go back to Eskimo mummies from around 1600, they were essentially non-detect. We
don’t have the information. There is a suggestion, Larry Needham told me about a month
ago that the CDC is looking at the levels today. Some of these levels are based upon stud-
ies that were samples that were collected maybe 10 years ago, and they think the levels are
a little bit lower. But we don’t have enough numbers to really firm that up.
Doug Dodge, Ontario Ministry of Natural Resources: Is there any reason to look at aboriginal
people in' a different way than we would look at the rest of the general population, in
terms of exposure and body burden? Were they lumped into that group?
Linda Birnbaum: Yes they are. We know that the Inuits in Hudson Bay have much higher body
burdens. Eric Dewailly from Quebec has actually measured PCB levels and he has done it ;
on a congener-specific basis and they have about 10 times the TEQ.
Doug Dodge: But could that similarly be a purpose for special application in the Great Lakes, v
for example, where there are aboriginal people just as dependent upon natural resources
as the Inuits?
Linda Birnbaum: Yes —— you people are much more familiar -- I know there is a Great Lakes
Initiative where you are looking at levels, for example, for certain Indian tribes and certain
subsistence ﬁsherman. In New York State, they are looking at the Akwesasne tribe of
Mohawk Indians, and‘trying to determine levels, but I don’t think their levels are turning
out to be higher than that of other people. The reason that the Inuits’ levels are so high is
because they eat sea mammals, and they eat blubber, and I think there have been some
comparisons done with the Cree, who live in the same area, but they don’t eat sea mam-
mals. They eat caribou and stuff like that, and their levels are not elevated. But I think we
are going to have questions of “what does it mean to be elevated.” Is two-fold enough? I
don’t know the answer to that.
18
 But, if someone would say to me “what is a great big research need?” I would say that we
need to develop some sort of better way to do biomonitoring, because right now it costs
$2,500 per sample to measure dioxins, furans and PCB levels. Well, you can’t do a lot of
samples and that is going to rapidly deplete everyone’s resources. We need to develop
some sort of methodology where we can get a measure which will be much more sensitive,
and much more cost effective, so that we can get a better handle on “do we have
populations where exposure is much higher than the general population.”
Doug Dodge: Things like the neurogenesis could be racially different, could it not, so you look
at different groups of people, you could get different effect levels.
Linda Birnbaum: I think that is an absolute possibility. When you deal with something like
immunotoxicity, clearly it is a multi-genic factor. Many things feed into how the immune
system works -- it is very easy to tickle it. I guess the Taiwanese data I find very important
because they do have people who are ethnically matched, but didn’t eat the rice oil. Much
of the rice oil was eaten in a very limited province and at a school in that province so they
really do have pretty good match controls there, where that wouldn’t really be much of a
problem. I think it is a problem with the Inuit study to find the appropriate controls. The
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